Technology

Allogene Therapeutics

$31.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.79 (-2.44%) Today
+$0.06 (+0.19%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ALLO and other stocks, options, and ETFs commission-free!

About ALLO

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA. The listed name for ALLO is Allogene Therapeutics, Inc. Common Stock.

CEO
David D. Chang
Employees
206
Headquarters
South San Francisco, California
Founded
2017
Market Cap
3.72B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.04M
High Today
$33.28
Low Today
$31.16
Open Price
$32.56
Volume
987.76K
52 Week High
$55.00
52 Week Low
$17.43

Collections

ALLO Earnings

-$0.68
-$0.45
-$0.23
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, Pre-Market

You May Also Like

NEE-Q
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure